Acute cardiac care & resuscitation
Danish-German cardiogenic shock trial—DanGer shock: Trial design update
Authors' conclusion
Main analyses of the primary and secondary outcomes of the DanGer Shock trial will be conducted according to this publication.
Study context
- Population
- Patients with AMICS shock due to STEMI undergoing emergency PCI
- Comparison
- Impella CP vs no Impella CP
- Primary endpoint
- All-cause death (ITT population: all randomised consented patients)
- Follow-up
- 180 days
Methodological detailsExploratory as-treated analysis of primary endpoint, No imputation of missing values, Secondary endpoints: composite of need for additional mechanical support, cardiac transplantation or all-cause death; days alive and out of hospital, Composite safety endpoint: major bleeding, vascular complications, device malfunction, aortic valve damage, significant hemolysis
- Exploratory as-treated analysis of primary endpoint
- No imputation of missing values
- Secondary endpoints: composite of need for additional mechanical support, cardiac transplantation or all-cause death; days alive and out of hospital
- Composite safety endpoint: major bleeding, vascular complications, device malfunction, aortic valve damage, significant hemolysis
Primary result
As reported in the abstract
- No results reported; primary endpoint to be analysed by Cox proportional hazards, reported as HR with 95% CI
- Intention to treat
Original publication
Danish-German cardiogenic shock trial—DanGer shock: Trial design update. Am Heart J. Published 19 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →